Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Qinglong Ma, Wenyang Zhang, Kongming Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
Ran Ni, Zhiming Hu, Ran Tao
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117430-117430
Open Access | Times Cited: 4
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
CASC8 activates the pentose phosphate pathway to inhibit disulfidptosis in pancreatic ductal adenocarcinoma though the c-Myc-GLUT1 axis
Hong-Fei Yao, Jieqiong Ge, Jiahao Chen, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
FOXM1-Driven CKS1B Upregulation Promotes Pancreatic Cancer Progression and Therapeutic Resistance
Li Zhang, Fang Wei, Qihui Sun, et al.
International Journal of Biological Sciences (2025) Vol. 21, Iss. 3, pp. 1047-1064
Open Access
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Toshifumi Doi, Takeshi Ishikawa, Michihisa Moriguchi, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
Pathway-specific genomic alterations in pancreatic cancer across diverse cohorts
Cecilia Monge, Brigette Waldrup, Francisco J. Carranza-Chávez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective
Vimal H. Prajapati, Ankit Kumar Singh, Adarsh Kumar, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
Leukemogenic Kras mutation reprograms multipotent progenitors to facilitate its spread through the hematopoietic system
Geunhyo Jang, Rosa Park, Eduardo Esteva, et al.
The Journal of Experimental Medicine (2025) Vol. 222, Iss. 6
Closed Access
Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway
Miao Hao, Tian‐Xing Zhang, Dan Dong, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access
The Persistent Power of the Taxane/Platin Chemotherapy
Lucy B. Xu, Elizabeth R. Smith, Vasili Koutouratsas, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1208-1208
Open Access
Deciphering cellular plasticity in pancreatic cancer for effective treatments
Md. Hafiz Uddin, Zhang Ding-qiang, Irfana Muqbil, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 393-408
Closed Access | Times Cited: 4
Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets
Yutong Zhao, C.M. Qin, Lin Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189183-189183
Closed Access | Times Cited: 3
Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: Towards potential anticancer therapy
S.L. Park, Venu Venkatarame Gowda Saralamma, Sagar D. Nale, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28495-e28495
Open Access | Times Cited: 2
Small molecular inhibitors: Therapeutic strategies for pancreatic cancer
Yuvasri Golivi, Seema Kumari, Batoul Farran, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104053-104053
Closed Access | Times Cited: 2
Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer
Jeffrey H. Becker, Anastasia E. Metropulos, Christina Spaulding, et al.
Cancer Research (2024) Vol. 84, Iss. 21, pp. 3629-3639
Open Access | Times Cited: 2
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96
Randa Mahran, Jonas N. Kapp, Salla Valtonen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 10, pp. 2152-2164
Closed Access | Times Cited: 2
MRTX1133’s promise for treating KRASG12D-mutant pancreatic cancer
Malak Haidar, Patrick Jacquemin
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 4, pp. 2002-2005
Open Access | Times Cited: 1
Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
Eszter Molnár, Marcell Baranyi, Krisztina Andrea Szigeti, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top